Skip to content

Recent Advancements and Approvals in Wet AMD Treatments

๐†๐ž๐ง๐ž๐ง๐ญ๐ž๐œ๐ก ๐ญ๐จ ๐‘๐ž๐ข๐ง๐ญ๐ซ๐จ๐๐ฎ๐œ๐ž ๐’๐ฎ๐ฌ๐ฏ๐ข๐ฆ๐จ ๐Ž๐œ๐ฎ๐ฅ๐š๐ซ ๐ˆ๐ฆ๐ฉ๐ฅ๐š๐ง๐ญ ๐Ÿ๐จ๐ซ ๐–๐ž๐ญ ๐€๐Œ๐ƒ
๐Ÿ’‰Genentech has announced the upcoming reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, designed for intravitreal use via an ocular implant to treat wet age-related macular degeneration (AMD). After a voluntary recall in October 2022 due to performance standard issues discovered during reliability testing, Genentech has made significant updates to the implant and refill needle. These enhancements ensure rigorous performance standards are met, with improvements implemented in manufacturing processes to boost reliability. Retina specialists and their patients in the United States can expect the availability of Susvimo in the coming weeks.

๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ ๐‘๐ž๐œ๐ž๐ข๐ฏ๐ž๐ฌ ๐”๐Š ๐€๐ฉ๐ฉ๐ซ๐จ๐ฏ๐š๐ฅ ๐จ๐Ÿ ๐‹๐ฒ๐ญ๐ž๐ง๐š๐ฏ๐š ๐Ÿ๐จ๐ซ ๐–๐ž๐ญ ๐€๐Œ๐ƒ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ
๐Ÿ‘ Outlook Therapeutics, Inc. has secured marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lytenava (bevacizumab gamma), a treatment for wet age-related macular degeneration (AMD). Lytenava is now the first and only authorized ophthalmic formulation of bevacizumab for wet AMD treatment in both the EU and UK. In collaboration with Cencora (formerly AmerisourceBergen), Outlook Therapeutics plans to support the global commercial launch of Lytenava, ensuring efficient distribution and accessibility for patients.

๐†๐ž๐ง๐ž๐ญ๐ž๐œ๐กโ€™๐ฌ ๐•๐š๐›๐ฒ๐ฌ๐ฆ๐จ ๐๐…๐’ ๐„๐š๐ซ๐ง๐ฌ ๐…๐ƒ๐€ ๐€๐ฉ๐ฉ๐ซ๐จ๐ฏ๐š๐ฅ ๐Ÿ๐จ๐ซ ๐‘๐ž๐ญ๐ข๐ง๐š๐ฅ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž๐ฌ
๐Ÿงช Genentech, a member of the Roche Group, has received FDA approval for Vabysmo Prefilled Syringe (PFS) for treating three potentially blinding retinal diseases. The Vabysmo 6.0 mg single-dose PFS delivers the same medicine as the previously available Vabysmo vials but in a more convenient, ready-to-use format. The approved indications for Vabysmo include wet AMD, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). This approval represents a significant step forward in providing effective treatments for these serious retinal conditions.